UK markets closed

LAVA Therapeutics N.V. (LVTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6200-0.1300 (-4.73%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.7500
Open2.6050
Bid2.4100 x 900
Ask2.7200 x 900
Day's range2.5100 - 2.7000
52-week range2.2800 - 8.3800
Volume11,644
Avg. volume8,711
Market cap67.532M
Beta (5Y monthly)N/A
PE ratio (TTM)0.27
EPS (TTM)9.8100
Earnings date15 Aug 2022 - 19 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est22.97
  • Globe Newswire

    LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

    Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at 2022 ASCO and EHA meetingsUTRECHT, The Netherlands and PHILADELPHIA, June 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, hosted a clinical update

  • Globe Newswire

    LAVA Therapeutics Announces Two Appointments to its Board of Directors

    James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companiesUTRECHT, The Netherlands and PHILADELPHIA, June 15, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the appointments of James Noble and Jay Backstrom, M.D., M.P.H., as

  • Globe Newswire

    LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

    UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY. Presen